Cancer reports最新文献

{"title":"Successful Diagnosis and Treatment of Early Postpartum Choriocarcinoma","authors":"Zeqing Du,&nbsp;Luyang Su,&nbsp;Sufen Zhao,&nbsp;Shizhao Wang","doi":"10.1002/cnr2.70328","DOIUrl":"https://doi.org/10.1002/cnr2.70328","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Postpartum placental choriocarcinoma is a rare gestational trophoblastic tumor, with an incidence of approximately one in 50 000. Patients often present with persistent postpartum hemorrhage, which can lead to delayed diagnosis, hematogenous metastasis, and ultimately, a poor prognosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 35-year-old woman was admitted to the Emergency Department 39 days after a cesarean section due to persistent heavy vaginal bleeding. Initial evaluation revealed a serum β-human chorionic gonadotropin (β-hCG) level of 7868 mIU/mL, transvaginal ultrasound identified a vascularized uterine mass with myometrial invasion, and MRI suggested residual tissue implantation. Following exclusion of retained products of conception, postpartum choriocarcinoma was suspected. The patient underwent five cycles of FAV chemotherapy (fluorouracil + actinomycin D + vincristine), resulting in undetectable β-hCG levels and resolution of imaging findings after two cycles. Three additional consolidation cycles were administered, with complete remission confirmed at the final follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pregnancy-related causes must always be ruled out in women of childbearing age who present with irregular vaginal bleeding, even during the postpartum and lactation periods. In patients with postpartum bleeding, vigilance should be heightened to rule out the possibility of a pregnancy-related Sertoli cell tumor.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70328","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144915225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Pre-Vaccination HPV Status on Vaccine Effectiveness Among Chinese Women: A Multicenter Cross-Sectional Study","authors":"Lucia Li,&nbsp;Haiyue Wu,&nbsp;Yibo Chen,&nbsp;Zhanjun Shen,&nbsp;Kun Fu,&nbsp;Minghui Qiu,&nbsp;Yingzhen Liu,&nbsp;Yufei Shen,&nbsp;Yingnan Lu,&nbsp;Xinxin Wen,&nbsp;Siyu Yang,&nbsp;Kehan Zou,&nbsp;Hui Zhang,&nbsp;Yangzong Gesang,&nbsp;Haojie Huang,&nbsp;Chao Zhao,&nbsp;Pengming Sun,&nbsp;Lisha Wu,&nbsp;Yu Zhang","doi":"10.1002/cnr2.70294","DOIUrl":"https://doi.org/10.1002/cnr2.70294","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Human papillomavirus (HPV) vaccines have been available in China for only 8 years, and routine HPV testing is not recommended prior to vaccination. Therefore, evaluation of HPV vaccine effectiveness and the impact of pre-vaccination HPV infection status on vaccine protective effect in Chinese women is warranted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From June 2022 to June 2023, women aged 18 to 50 years without a history of cervical or uterine excision were recruited from three medical institutions. Baseline characteristics were compared between vaccinated and unvaccinated participants, with inverse probability treatment weighting (IPTW) applied to adjust for confounding factors. HPV infection rates and vaccine effectiveness (VE) were calculated. Additionally, a sub-group analysis was conducted among vaccinated women to explore the impact of pre-vaccination HPV infection status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After adjusting for group differences, the vaccine effectiveness against new HPV16/18 infections was 76.1% (95% CI: 58.7%–86.2%) among 2285 participants. Older age and possession of a master's degree or higher were identified as protective factors, whereas increased parity and exclusive use of oral contraceptives were determined to be risk factors for HPV16/18 infection. Women with unknown pre-vaccination HPV status exhibited significantly higher post-vaccination rates of high-risk HPV infections (RR 4.278, 95% CI: 2.537–7.215) compared to those who were HPV-negative prior to vaccination. However, no significant difference in new high-risk HPV infection rates was observed between pre-vaccination HPV-negative and HPV-positive women.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In addition to HPV vaccination, factors such as age, parity, exclusive use of oral contraceptives, and higher education attainment were independently associated with HPV16/18 infection rates. Pre-vaccination HPV infection status did not significantly influence the protective efficacy of the HPV vaccine against previously unencountered HPV types.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70294","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144915113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between MRI and Histopathology in Assessing Treatment Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer","authors":"Pedram Fadavi,&nbsp;Kambiz Novin,&nbsp;Maryam Garousi,&nbsp;Amir Mohammad Arefpour,&nbsp;Seyedeh Shaghayegh Rezvani Nezhad,&nbsp;Mahshid Soori,&nbsp;Farzad Taghizadeh-Hesary","doi":"10.1002/cnr2.70322","DOIUrl":"https://doi.org/10.1002/cnr2.70322","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Recognizing the predictive factors of response to chemoradiation is of utmost importance in patients with locally advanced rectal cancer (LARC). The study is designed to explore the correlation between post-neoadjuvant chemoradiation (nCRT) pathologic and MR-based tumor staging in LARC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with non-metastatic LARC underwent contrast-enhanced pelvic MRI before and after treatment, received standard chemoradiation, and were evaluated for tumor response. Tumor regression grade (TRG) based on histopathology ranged from TRG0 to TRG3, while MR-based responses encompassed complete response, partial response, stable disease, and progressive disease. The primary endpoints were the correlation and agreement between post-nCRT histopathologic- and MR-based tumor staging. The secondary endpoints focused on predictive factors influencing the response to nCRT and assessing the effectiveness of MRI in identifying complete pathologic response (pCR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The analysis showed a strong positive correlation (<i>r</i> = 0.86, <i>p</i> &lt; 0.001) with moderate agreement (κ = 0.44) between post-nCRT MR- and histopathologic-based disease staging. According to multivariate analysis, initial tumor stage could predict clinical response to nCRT, and MR-based TRG could predict histopathologic response. MRI exhibited a specificity of 96.2%, sensitivity of 22.2%, positive predictive value of 50%, and negative predictive value of 88.1% in detecting pCR.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The study highlights the promising role of MRI in assessing treatment response in LARC, guiding clinical decision-making and potentially reducing the need for invasive procedures to evaluate treatment effectiveness.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70322","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144914922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast Cancer","authors":"Seema Nagpal,&nbsp;Kim-Son Nguyen,&nbsp;Sophie Bertrand,&nbsp;Kristen May Cunanan,&nbsp;Sukhmani K. Padda,&nbsp;Judy Y. Pagtama,&nbsp;Alison Holmes Tisch,&nbsp;Gwen Coffey,&nbsp;Reena P. Thomas,&nbsp;George W. Sledge Jr,&nbsp;Joshua Gruber,&nbsp;Melinda L. Telli,&nbsp;Mark Pegram,&nbsp;Lawrence D. Recht,&nbsp;Heather A. Wakelee,&nbsp;Scott G. Soltys,&nbsp;Suleiman A. Massarweh,&nbsp;Joel W. Neal","doi":"10.1002/cnr2.70330","DOIUrl":"https://doi.org/10.1002/cnr2.70330","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Brain metastases are common in patients with lung and breast cancer and are associated with poor outcomes. While there is some intracranial activity with systemic therapies, most chemotherapies are minimally effective. Etirinotecan pegol (EP) is a PEGylated chemotherapy with favorable pharmacokinetics over irinotecan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a phase 2 trial of EP in patients with previously treated metastatic non-small cell lung cancer (NSCLC, <i>n</i> = 12), small cell lung cancer (SCLC, <i>N</i> = 3) and breast cancer (MBC, <i>n</i> = 12), having progressive brain metastases after brain-directed radiotherapy (or refusal). The primary endpoint was a 25% or greater disease control rate, defined as CR, PR+SD, in the central nervous system (CNS) at 12 weeks; secondary endpoints included toxicity and systemic disease control.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The CNS control rate at 12 weeks in NSCLC and MBC was 17% (two patients in each cohort) and 0% in SCLC. The median overall progression-free survival for NSCLC was 2.7 months (95% CI: 1.3, 6.7) and MBC was 1.4 months (95% CI: 1.3, 6.9). The most common adverse events were diarrhea (48%), nausea (48%) and fatigue (26%). Six patient deaths occurred in this study. Dehydration/diarrhea (1) and neutropenic sepsis (3) from study treatment were at least possibly related to these deaths.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study demonstrates that EP did not meet the threshold of clinical efficacy in patients with refractory CNS metastases from lung or breast cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70330","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144915114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Risk of HPV-Associated Oropharyngeal Cancers in Husbands of Women With Anogenital Cancer","authors":"Tuomas Lehtinen,&nbsp;Luayo Zhang,&nbsp;Kristina Sundquist,&nbsp;Jan Sundquist,&nbsp;Tim Waterboer,&nbsp;Matti Lehtinen,&nbsp;Kari Hemminki","doi":"10.1002/cnr2.70333","DOIUrl":"https://doi.org/10.1002/cnr2.70333","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Human papillomavirus (HPV) infection is associated with tonsillar and base-of-tongue squamous cell carcinomas (TSCC/BOTSCC). We evaluated the relative risk (RR) of TSCC/BOTSCC in the husbands of women with anogenital cancer using the Swedish family database.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Swedish family database includes 3.5 million families and 16 million individuals identified since 1932 and linked to cancer data from 1958 to 2015. We explored the RR of TSCC/BOTSCC in husbands of women diagnosed with anogenital (anal, vulvar/vaginal, cervical) cancer or cervical carcinoma in situ (CIS) as compared to husbands of controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The RR of TSCC/BOTSCC in husbands of women with invasive anogenital cancer increased by calendar time and decreasing ages at diagnoses. In 2002–2015, the RR peaked at 5.35 (95% CI 2.21–13.0) in TSCC/BOTSCC cases diagnosed at age &lt; 50 years. In husbands of women with CIS, the RR for TSCC/BOTSCC was 2-fold irrespective of time period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Clustering of increased HPV-associated invasive cancer risk in spouses appears to be calendar-time dependent. This introduces a new perspective in cancer science: an increase of familial HPV-associated cancer risk in spouses.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70333","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144915224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: A Bilateral Synchronous Primary Non-Small Cell Lung Cancer Patient With Two Different EGFR Mutations","authors":"Thanh-Dung Quach,&nbsp;Kien Hung Do,&nbsp;Dinh Tung Nguyen,&nbsp;Hyeon-Gyu Yi,&nbsp;Thi-Phuong Vu,&nbsp;Tran Thanh Tin,&nbsp;Nghi Le Vinh,&nbsp;Son Hai Vu","doi":"10.1002/cnr2.70319","DOIUrl":"https://doi.org/10.1002/cnr2.70319","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Non-small cell lung cancer (NSCLC) represents the majority of lung cancer cases, with epidermal growth factor receptor (EGFR) mutations playing a crucial role in disease prognosis and treatment. Around half of Asian patients with NSCLC, particularly non-smoking women, have EGFR mutations. These patients with NSCLC typically exhibit a single EGFR mutation in exon 18, 19, 20, or 21. It is extremely rare for patients with bilateral primary NSCLC to harbor two different EGFR mutations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We report a case of 70-year-old non-smoking Vietnamese female patient diagnosed with synchronous bilateral primary NSCLC, each harboring different EGFR mutations—G719C in exon 18 in the right lung and an exon 19 deletion in the left lung. The patient underwent surgical resection of the left lung lesion, followed by targeted therapy with afatinib for the right lung lesion, which resulted in tumor reduction and disease stability for 1 year before disease progression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study underscores the complexity of diagnosing and managing synchronous bilateral NSCLC with distinct genetic profiles. This report also highlights the importance of comprehensive molecular profiling to select an optimal treatment strategy to improve patient outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70319","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144897317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Epidermal Growth Factor Receptor 2 [HER-2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran","authors":"Samaneh Salarvand,&nbsp;Abbas Mohammadi,&nbsp;Reza Shahsiah,&nbsp;Farzaneh Bagheri,&nbsp;Mahsa Gholizadeh,&nbsp;Somayeh Jolany-Vangah,&nbsp;Ebrahim Esmati,&nbsp;Marzieh Lashkari,&nbsp;Vahid Soleymani,&nbsp;Seraj Zareh-Dehabadi,&nbsp;Vahid Mehrtash,&nbsp;Amirmohsen Jalaeefar,&nbsp;Mohammad Shirkhoda,&nbsp;Moones Toosang,&nbsp;Romina Abyaneh,&nbsp;Reza Ghalehtaki","doi":"10.1002/cnr2.70314","DOIUrl":"https://doi.org/10.1002/cnr2.70314","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Molecular targeted therapy and immunotherapy have shown promise in managing gastric adenocarcinoma. The amplified expression of Human epidermal growth factor receptor-2 (HER-2) and microsatellite stable (MSI) status serve as indicators of response to targeted therapy and immunotherapy, respectively.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study assessed the frequency of MSI status and HER-2 expression in a pretreated sample of Iranian patients with gastric and gastroesophageal (GE) adenocarcinoma.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods and Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We conducted HER-2/neu expression and mismatch repair (MMR) system analyses on specimens from patients with gastric and GE adenocarcinoma at the Cancer Institute of Iran. Archival tissues from 135 mainly pre-treated surgical specimens of gastric adenocarcinoma cases were used for HER-2 analysis, and 66 specimens were used for MSI analysis. All specimens were tested for HER-2 amplification, revealing that 11 patients (8.1%) had HER-2 amplification, and three out of 66 examined patients exhibited MSI-H. Patients with HER-2 overexpressed specimens had a shorter median overall survival (OS) compared with HER-2 negative cases (21 months (95% CI: 1.4–40.6) vs. 31 months (95% CI: 22.9–39), &lt;i&gt;p&lt;/i&gt; = 0.18). The median disease-free survival (DFS) for HER-2 positive and negative patients was 15 and 28 months, respectively (&lt;i&gt;p&lt;/i&gt; = 0.25). The estimated median OS and DFS for patients with negative MSI were 26 and 20 months, respectively. However, none of the patients with MSI-positive status experienced recurrence, metastases, or death within the follow-up period; thus, MSI-H patients had a significantly improved OS and DFS (&lt;i&gt;p&lt;/i&gt; = 0.018 and 0.020).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;HER-2 expression, while less common in our Iranian population compared with North American or Western European countries, showed a nonsignificant trend toward poor outcomes in patients with gastric adenocarcinoma. MSI-H status was highly infrequent in our population, suggesting that immunotherapy may not be a beneficial treatment for a significant fraction of Iranian patients with gastric adenocarcinoma. However, a minority may still benefit from it. MSI-H was associated with reduced perineural invasion and improved OS and DFS. Therefore, this hypothesis warrants further investigation in clinical trials to underscore the prognostic significance of HER-2 and MSI status and the value of molecular profiling in guiding personalized treatment strategies.&lt;/p&gt;\u0000 ","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70314","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144894160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Catheter Ablation for Atrial Fibrillation in Breast Cancer Survivors: An Exploratory Observational Study Using the French Nationwide Health Care Database Sample","authors":"Laura Saint-Lary,&nbsp;Juliette Thariat,&nbsp;Baptiste Pinel,&nbsp;Gaëlle Jimenez,&nbsp;Marie-Odile Bernier,&nbsp;Loïc Panh,&nbsp;Serge Boveda,&nbsp;Sophie Jacob","doi":"10.1002/cnr2.70320","DOIUrl":"https://doi.org/10.1002/cnr2.70320","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Catheter ablation is a key treatment for atrial fibrillation (AF). This procedure is clearly identifiable in French medical-administrative databases and can be used as a surrogate for symptomatic patients with drug-refractory or symptomatic paroxysmal AF forms. Breast cancer (BC) patients have an increased risk of AF, but knowledge about AF forms treated by ablation is limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Based on a representative cohort of BC patients from the French National Health Databases, we aimed to assess the occurrence of AF catheter ablation in these patients, compared to the general population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with a first diagnosis of BC between 2008 and 2018 and followed for at least 1 year until 2019 were eligible. The incidence rates of AF ablation among BC patients were compared to those in the general population by estimating a standardized incidence ratio (SIR). A competing risk survival model was used to evaluate the occurrence of AF ablation in BC patients treated with or without radiotherapy (RT) (subdistribution Hazard Ratio—sdHR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We included 3667 patients (78% with RT). Overall, 16 cases underwent AF ablation, whereas 8.3 cases were expected in the general population, resulting in a significant SIR of 1.93 [1.10–3.00] (<i>p</i> &lt; 0.05). After a mean follow-up of 6.6 years, the cumulative incidence of AF ablation at 5 years was 0.14% [0.05–0.35] in the RT group and 0.47% [0.13–1.31] in the non-RT group, with no significant difference in the age-adjusted survival analysis (sdHR = 0.65 [0.21–2.01]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our exploratory study revealed that BC patients had a twofold greater rate of first AF ablation than the age-comparable general population, without a link with RT. These results should be interpreted cautiously because of the limited size of the study population and the differing characteristics between the RT and non-RT groups.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70320","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144897318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single Pontine Relapse Shortly After Hippocampal Avoidance Whole Brain Radiotherapy: A Case Report","authors":"Zeinab Dandash,&nbsp;Bassem Youssef,&nbsp;Ali Al Zein,&nbsp;Arafat Tfayli,&nbsp;Toni Tannoury,&nbsp;Lara Hilal","doi":"10.1002/cnr2.70323","DOIUrl":"https://doi.org/10.1002/cnr2.70323","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Brain metastasis represents the most prevalent form of brain tumors in adults, with a rising incidence resulting from significant advancements in cancer detection and therapeutic interventions. Current treatment protocols advocate for whole brain radiotherapy (WBRT) for patients who are not candidates for either surgical resection or stereotactic irradiation. However, cognitive decline remains a major side effect of this treatment modality. Hippocampal-sparing WBRT (HA-WBRT) has been shown to decrease brain toxicity, with the main concern being the probability of developing new brain metastasis in the hippocampal avoidance region.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We report a case of a 73-year-old male presenting with multiple brain metastases and treated with HA-WBRT, who then developed a new single pontine lesion shortly after that was found to be located in an under-dosed peri-hippocampal area. We dosimetrically compared the patient's original IMRT plan to three new plans: a standard VMAT plan, an optimized IMRT plan, and an optimized VMAT plan, where optimization incorporated brainstem coverage as a planning objective, resulting in a notable improvement in brainstem dose distribution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HA-WBRT poses a risk of peri-hippocampal metastasis due to underdosing of the upper brainstem that is inherent in HA-WBRT plans. Planning techniques should focus on optimizing coverage of the brainstem in an attempt to decrease this uncommon occurrence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70323","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144894141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Homozygous FANCM Variant c.5101C>T p.(Gln1701*) in a Patient With Early Onset Breast Cancer, Chemotherapy Toxicity, and Chromosome Fragility: A Case Report","authors":"Sonja Sulkava,&nbsp;Anna H. Hakonen,&nbsp;Rikke Christensen,&nbsp;Minna Pöyhönen,&nbsp;Heli Nevanlinna","doi":"10.1002/cnr2.70283","DOIUrl":"https://doi.org/10.1002/cnr2.70283","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Biallelic <i>FANCM</i> variants are linked to a Fanconi anemia-like cancer predisposition syndrome, which includes early onset breast cancer, chemotherapy toxicity, and chromosome fragility. Additionally, heterozygous truncating variants have been linked to increased breast cancer risk. However, the published results have been inconsistent, and the risks and the functional effects associated with the variants also vary depending on the position in the gene, with N-terminal truncating variants having a stronger effect. Compared to other <i>FANCM</i> variants studied, milder patient phenotypes and only late onset breast cancer have been reported for the homozygous C-terminal c.5101C&gt;T variant, which is enriched in Finland.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We report here a Finnish patient, homozygous for the <i>FANCM</i> c.5101C&gt;T p.(Gln1701*) variant, who manifested with early onset triple-negative breast cancer, chemotherapy toxicity, and chromosome fragility. Homozygosity for c.5101C&gt;T has previously been reported in two Finnish siblings with primary ovarian insufficiency and chromosome fragility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings suggest that the C-terminal <i>FANCM</i> variant c. 5101C&gt;T may also be linked to a phenotype similar to the phenotype associated with N-terminal truncating variants when inherited in a homozygous state.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70283","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144869966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}